Details of the Drug

General Information of Drug (ID: DMM1Z9G)

Drug Name
Vutrisiran
Synonyms ALN-TTRsc02
Indication
Disease Entry ICD 11 Status REF
Hereditary amyloidosis 5D00.2 Approved [1]
Transthyretin familial amyloid cardiomyopathy 5D00.20 Phase 3 [2]
Affected Organisms
Humans and other mammals
ATC Code
N07XX18: Vutrisiran
N07XX: Other nervous system drugs
N07X: OTHER NERVOUS SYSTEM DRUGS
N07: OTHER NERVOUS SYSTEM DRUGS
N: NERVOUS SYSTEM
Drug Type
Small interfering RNA
Sequence
>Subunit 1
UGGGAUUUCAUGUAACCAAGAX
>Subunit 2
UCUUGGUUACAUGAAAUCCCAUC
Cross-matching ID
UNII
GB4I2JI8UI
DrugBank ID
DB16699
TTD ID
DXRP68

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Transthyretin messenger RNA (TTR mRNA) TTPOYU7 TTHY_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215515.
2 ClinicalTrials.gov (NCT03759379) HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals.